Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 299, Issue 1, 2001, Pages 83-89

  Rauser, Laura ^a   Savage, Jason E ^a   Meltzer, Herbert Y ^b   Roth, Bryan L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMITRIPTYLINE; AMPEROZIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; ISOPROTEIN; KETANSERIN; LOXAPINE; MELPERONE; MESORIDAZINE; MIANSERIN; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; RITANSERIN; RNA; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SERTINDOLE; SULPIRIDE; TIOTIXENE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHIZOPHRENIA;

3T3 CELLS; ANIMALS; ANTIPSYCHOTIC AGENTS; COS CELLS; HUMANS; HYDROLYSIS; MICE; PHOSPHATIDYLINOSITOLS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RNA EDITING; SEROTONIN AGONISTS; TRANSFECTION;

EID: 0034806737     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands
2. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
3. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia
4. Radioreceptor binding profile of the atypical antipsychotic olanzapine
5. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: Clozapine potently interacts with 5-HT1C sites
6. Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: A comparison to other antipsychotics
7. Placebo-controlled clinical trial of remoxapride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation
8. Pharmacological data of the atypical neuroleptic melperone
9. Amperozide: A new pharmacological approach in the treatment of schizophrenia
10. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
11. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
12. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
13. Creation of a constitutively activated state of the 5-HT2A receptor by site-directed mutagenesis: Revelation of inverse agonist activity of antagonists
14. Zotepine for schizophrenia
15. Fluperlapine in 104 schizophrenic patients. Open multicenter trial
16. Fluperlapine vs haloperidol: A comparison of their neuroendocrinological profiles and the influence on serum lipids
17. A clinical comparison of melperone and placebo in schizophrenic women on a milieu therapeutic ward
18. Pharmacological characterization of the constitutively activated state of the serotonin 5-HT2C receptor
19. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors
20. Pharmacology of risperidone (R 64,766) a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties
21. A highly conserved aspartic acid (D155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT2A serotonin receptor but does not participate in activation via a 'salt-bridge disruption' mechanism
22. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs
23. Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells
24. Catching up on schizophrenia. Natural history and neurobiology
25. Outcome in schizophrenia: Beyond symptom reduction
26. The role of serotonin in antipsychotic drug action
27. Suicide and schizophrenia: Clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial
28. The pharmacoeconomics of clozapine: A review
29. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values
30. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
31. Neuroendocrine studies in psychiatric disorders: The role of serotonin
32. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors
33. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity
34. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding
35. Potency of antiphychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity
36. Modulation of phosphatidylinositol-4,5-bisphosphate hydrolysis in rat aorta by guanine nucleotides, calcium and magnesium
37. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors
38. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
39. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors
40. Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover
41. 5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: Modulation of phosphoinositide turnover by phorbol ester
42. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs
43. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
44. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons
45. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
46. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists
47. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: Results of an open clinical trial and changes of neuroendocrinological and EEG parameters
48. Muscarinic m4 receptor activation by some atypical antipsychotic drugs